RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Net income

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndNet income (Million USD)YoY (%)
Dec 31, 2024-278-36.82%
Dec 31, 2023-440-61.08%
Dec 31, 2022-1,131+32.64%
Dec 31, 2021-853-0.64%
Dec 31, 2020-858-3.14%
Dec 31, 2019-886+16.37%
Dec 31, 2018-761+55.13%
Dec 31, 2017-491+19.69%
Dec 31, 2016-410+41.38%
Dec 31, 2015-290-19.51%
Dec 31, 2014-360+303.92%
Dec 31, 2013-89-15.84%
Dec 31, 2012-106+83.90%
Dec 31, 2011-58+32.48%
Dec 31, 2010-44

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)